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Effects of Peritransplant Administration of Hematopoietic Growth 
Factors on the Development of Chronic Allograft Rejection 
M. Terakura, Q. Ye, N. Ichikawa, A.J. Demetris, T. Sakamoto, Z. Liu, T.E. Starzl, and N. Murase 
CHRONIC allograft rejection (CR) remains as the 
major obstacle to successful organ transplantation. 
We have previously shown that persistence of donor mul-
tilineage hematolymphoid cells after transplantation corre-
lates with the resistance to CR.1- 3 We hypothesized in this 
study that perioperative administration of hematopoietic 
growth factors will be able to augment donor chimerism and 
therefore ameliorate the development of CR. This hypoth-
esis was examined using a rat heart transplantation model 
with simultaneous donor bone marrow (BM) infusion. 
METHODS 
Female Brown-Norway (BN, RTI n) rats received heterotopic heart 
grafts from male Lewis (LEW, RTll) donors. Recipients also 
received intravenous infusion of donor BM (2.5 x 108) harvested 
from the tibias and femurs on the day of transplantation and were 
treated with intramuscular tacrolimus (1.5 mglkg per day, Fujisawa 
Pharmaceutical Co., Ltd, Osaka, Japan) on days 0 to 13,20, and 27, 
Six groups of animals were examined using four different hemato-
poietic growth factors, including rh-granulocyte colony stimulating 
factor (G-CSF. Amgen, Thousand Oaks, Calif), rh-granulocyte 
microphage colony stimulating factor (GM-CSF, Immunex, Seat-
tle, Wash), rh-Flt-3 ligand (Immunex) and rh-IL-6 mutein 
(ImClone System Inc., Somerville, NJ) (Table 1). Levels of chimer-
ism were semiquantitatively analyzed by polymerase chain reaction 
and Southern hybridization using rat sex determining region-Y 
(SRY) specific oligonucleotide primers4 in sequential blood sam-
ples and recipient tissues at sacrifice on day 100 after transplanta-
tion. Heart allografts were further histopathologically analyzed for 
the severity of CR. 
RESULTS 
Donor BM infusion alone significantly increased male DNA 
concentration in the blood for the first 2 months after 
grafting. Additional treatment with growth factors did not 
show further significant augmentation of blood chimerism. 
At day 100, donor male DNA was not detected in the 
peripheral blood of any recipient, but it was found more 
frequently in recipient tissues such as the skin, native heart, 
and spleen. Level and frequency of chimerism were signif-
icantly increased in recipients with adjunctive BM infusion 
and further augmented by Flt-3 ligand and IL-6 treatment 
(Table 1). Histopathologic analysis of heart allografts at day 
100 revealed the significant amelioration of overall inflam-
mation in BM-infused recipients compared to uninfused 
controls (Table 1). Evaluation of arterial changes demon-
strated the significant improvement of the degree of oblit-
erative arteriopathy in BM-infused recipients treated with 
G-CSF and IL-6 (Table 1). Additionally, when samples 
from all cardiac allografts of six groups were pooled and the 
histopathologic changes were correlated with the pooled 
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Table 1. Effects of Adjunctive Donor Bone Marrow Infusion and Perioperative Administration of Hematopoietic Growth Factors on 
Levels of Chimerism and Histopathologic Changes of Chronic Allograft Rejection 
Group Transplantation Growth Factor Dose (kg/d) 
HTX None NA 
2 HTX + 8M None NA 
3 HTX + 8M G-CSF 200/Lg 
4 HTX + 8M GM-CSF 200 /Lg 
5 HTX + 8M Flt-3 ligand 200 /Lg 
6 HTX + 8M IL-6 500/Lg 
All values are mean :!: SE. 
'In native heart at 100 days after transplantation. 
P values vs HTX (group 1): t <.001; * <.0001; vs HTX + BM (group 2): ~ <.05. 
Abbreviation: OA: obliterative arteriopathy. 
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levels of chimerism in the native hearts of these same 
animals, significant inverse correlation was found between 
the severity of CR (inflammation score and arterial 
changes) and levels of chimerism. 
DISCUSSION 
It was determined in this study whether there was a 
correlation between the quantity and localization of chimer-
ism and severity of CR using histopathologic endpoints and 
PCR analysis of Y -chromosome in sex-mismatched trans-
plantation. Results demonstrate that CR was reduced in 
inverse proportion to the amount of detectable chimerism, 
whieh in turn was greater in animals given adjunct BM and 
postoperative growth factor therapy. Differences among 
growth factors in increasing chimerism and preventing CR 
were not significant, but chimerism tended to be greater 
with Flt-3 ligand and IL-6. Trends of reduced CR were seen 
with G-CSF and IL-6 treatment. G-CSF and GM-CSF 
already have been widely used in clinical bone marrow 
871 
transplant recipients and after cancer chemotherapy. The 
administration of G-CSF and GM-CSF long after trans-
plantation to stable organ recipients has not increased the 
risk of either rejection of GVHD. This study demonstrates 
that pcrioperative hematopoietic growth factor treatment is 
effective in enhancing the level of chimerism and improving 
histopathologic abnormalities associated with CR. Preclin-
ical laboratory studies under controlled circumstances will 
be doubly important to further improve the method to use 
growth factors for CR. 
REFERENCES 
1. Murase N, Starzl TE, Tanabe M, et al: Transplantation 
60:158, 1995 
2. Dcmetris AJ, Murase N. Ye Q, et al: Am J Pathol 150:563, 
1997 
3. Starzl TE, Demetris AJ. Murase N, et al: Immunol Today 
17:577, 1996 
4. Tashiro H, Fukuda Y, Kimura A, et al: Transplantation 
58:745, 1994 
